Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients

BACKGROUND: Immune checkpoint therapy has dramatically changed the landscape of cancer therapy, providing an efficacious and durable therapeutic option for patients with advanced-stage disease. However, dermatologic toxicities are a well-recognized side effect in patients receiving this therapy. A s...

Descripción completa

Detalles Bibliográficos
Autores principales: Tetzlaff, Michael T., Nelson, Kelly C., Diab, Adi, Staerkel, Gregg A., Nagarajan, Priyadharsini, Torres-Cabala, Carlos A., Chasen, Beth A., Wargo, Jennifer A., Prieto, Victor G., Amaria, Rodabe N., Curry, Jonathan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810034/
https://www.ncbi.nlm.nih.gov/pubmed/29433571
http://dx.doi.org/10.1186/s40425-018-0323-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810034/
https://www.ncbi.nlm.nih.gov/pubmed/29433571
http://dx.doi.org/10.1186/s40425-018-0323-0

Ejemplares similares